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INTRODUCTION
Gastrointestinal manifestations are common in patients 
with systemic lupus erythematosus (SLE), and the incidence 
of these conditions varies according to the methods of 
evaluation and the type of manifestation; the incidence of 
gastrointestinal manifestations varied between 15% and 
75% in the majority of previously published studies.1,2 The 
clinical picture may vary from minor symptoms, such as 
oral ulcers, dysphasia, nausea and vomiting, to more serious 
conditions, including pancreatitis, hepatitis and mesenteric 
vasculitis. 
Mesenteric vasculitis is uncommon among gastro-
intestinal complications (2.2-9.7%) but may cause enhanced 
complications and mortality if it is not carefully diagnosed 
and promptly treated.1
Gastrointestinal vasculitis is characterized by ischemia of 
the digestive tract; this ischemia is caused by the deposition 
of circulating immune complexes. Clinically, this vasculitis 
presents with diffuse abdominal or colonic pain, vomiting 
and fever. The physical examination demonstrates abdominal 
pain upon touching, which may indicate peritoneal 
irritability. Gastrointestinal vasculitis does not usually appear 
as an isolated manifestation but is generally associated with 
other clinical manifestations of the illness and SLE activity. 
Consequently, the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI) score is generally high in patients 
with gastrointestinal vasculitis.1,3-7 
In the present study, we describe an unusual case of 
a lupus patient with mesenteric vasculitis who presented 
without any evidence of the illness, which is usually found 
in this clinical situation. 
CASE DESCRIPTION
In 1986, a 45-year-old female with two sisters who 
had suffered and died from SLE presented with symptoms 
of fatigue, fever, alopecia, facial edema, Raynaud’s 
phenomenon, malar rash, polyarthritis of the great and small 
joints, leukopenia and lymphopenia. The patient had positive 
antinuclear antibody levels > 1:200, with a speckled pattern, 
and also had positive anti-ENA and anti-Sm antibodies. 
Thus, she was diagnosed with SLE. Treatment was initiated 
with chloroquine diphosphate (250 mg/day) and prednisone 
(30 mg/day). All manifestations regressed, except for the 
leukopenia and lymphopenia. The leukopenia continued and 
was not linked with the illness. The results of a myelogram 
were normal. 
In January, 2001, the patient visited the clinic 
complaining of abdominal pain, nausea, anorexia, vomiting 
and abdominal distension. At the time, the patient was only 
receiving prednisone (5 mg/day) and was suffering from 
arterial hypotension. After expanding the vascular volume 
with crystalloids, she promptly recovered. After several days, 
she returned to the hospital for follow up but did not present 
with any abdominal pain. Physical examination showed 
the patient to be without fever, any evidence of cutaneous 
lesions, arthritis or cutaneous vasculitis, and her abdomen 
was normal. On that occasion, laboratory tests showed 
the following: hemoglobin 10.7 g/dL, hematocrit 32%, 
leukocytes 2,600/mL (neutrophils, - 1,700/mL, lymphocytes 
- 600/mL), platelets 177,000/mL, amylase 156 U/L (normal 
value < 100 U/L), lipase 419 U/L (normal value < 190 U/L), 
aspartate amino transferase (AST) 15 U/L, alanine amino 
transferase (ALT) 25 U/L, gamma glutamyl transferase 
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(GGT) 21 U/L, alkaline phosphatase 86 U/L, bilirubin 
0.9 mg/dL and albumin 4.1 g/L. The urine examination 
showed isolated proteinuria without hematuria, leukocyturia 
or cylindruria. The protein quantity in urine collected 
over a 24-hour period was 1.48 g. Urea (31 mg/dL) and 
creatinine (0.9 mg/dL) levels were normal. The erythrocyte 
sedimentation rate was 26 mm/1st hour. C-reactive protein, 
gamma-globulin and complement were within the normal 
ranges. Anti-dsDNA antibodies, anti-cardiolipin IgG and 
IgM, lupus anticoagulant, anti-beta-2-glycoprotein I IgG 
and IgM, cryoglobulinemia, and anti-endothelial cell 
antibodies were not detected. The SLEDAI score on this 
occasion was low (two) because of the new proteinuria; the 
leukopenia was already chronic. Because the complement 
levels were normal, anti-dsDNA antibodies were not present, 
urine sedimentation was inactive, and creatinine levels and 
blood pressure were normal, enalapril was initiated and the 
abdominal pain was investigated. An abdominal x-ray was 
normal, and an abdominal ultrasound verified a right pyelo-
ureteral distention without any evidence of nephrolithiasis. 
These results were confirmed by an abdominal computerized 
tomography (CT) scan. The patient was well and was 
discharged for a follow up at the outpatient clinic. 
The patient continued to suffer from sporadic episodes 
of light abdominal pain and was again hospitalized in 
April, 2001. At this time, she presented sensitivity to 
abdominal touching, without peritonism. She did not 
show any evidence of clinical SLE activity. The laboratory 
tests showed increased levels of the pancreatic enzymes 
amylase (135 U/L) and lipase (469 U/L). Urine analysis 
showed no alterations. Complement levels were reduced, 
with undetectable C4 and C3. Anti-dsDNA antibodies were 
present (1:80), and at this time, her SLEDAI was four. The 
new abdominal CT showed discrete ascites and diffuse 
jejunoileal thickening, with the “target sign,” suggestive of 
an ischemic process that takes place in the microvasculature 
(Figure 1). Radiological examination of intestinal transit 
showed a delay in the transit time in the small bowel 
and distension of the handles, suggesting an intestinal 
occlusion. A digital arteriography scan was performed and 
showed microaneurysmatic distal distensions and zones of 
hypervascularization, suggestive of vasculitis in the superior 
mesenteric artery territory (Figure 2); the proximal region of 
this artery, the celiac trunk and the inferior mesenteric artery 
were normal. In its delayed phase, right hydronephrosis 
was evident (Figure 3). Thus, the diagnosis of mesenteric 
vasculitis was confirmed. 
Methylprednisolone (50 mg/day, intravenous) was 
initiated, and the patient showed clinical improvement and 
became asymptomatic after four days. A new abdominal 
CT was performed to evaluate her progress, and the results 
Figure 1 - Abdominal computerized tomography showing dilated bowel, 
focal or diffuse bowel wall thickening, and abnormal bowel wall enhance-
ment (a double halo or target sign).
Figure 2 - Digital arteriography showing hypervascularization and multiple 
microaneurysms in the branches of the superior mesenteric artery, which is 
compatible with vasculitis.
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were normal. After two weeks of corticosteroid therapy, 
intravenous cyclophosphamide (1 g) was given monthly for 
one year. The patient had a gradual and complete control 
of illness, thereby allowing the tapering of corticosteroid 
therapy. She also received cyclophosphamide pulse therapy 
twelve times in a period of one year. Currently, she is well 
and in SLE remission. 
DISCUSSION
Mesenteric vasculitis is an extremely serious 
complication and is highly lethal (50%)2 during the course 
of SLE. Quickly recognizing mesenteric vasculitis changes 
the prognosis, as the fast introduction of therapy changes the 
course of the illness. 
From a histopathological point of view, mesenteric 
vasculitis is an inflammatory process of the vascular wall, 
with fibrinoid necrosis that drives regional ischemia and 
dysfunction of the intrinsic intestinal musculature. This 
condition is characterized by the deposition of complement, 
fibrinogen and immune complexes.6 
Clinically, mesenteric vasculitis can present as abdominal 
angina, pain in the colon, distension and pseudo-blockage. 
Laboratory tests show increased inflammatory symptoms. 
The x-rays and abdominal transit results can be compatible 
with bowel pseudo-obstruction, as in the present case. 
Abdominal CT with contrast is employed to help with the 
diagnosis and was used in the present case to show favorable 
progress. In 1997, Ko et al.8 demonstrated the importance 
of CT as a basic and decisive diagnostic instrument in 
lupus patients with abdominal pain. The authors studied 15 
SLE patients for up to 4 days from the initiation of pain. 
Of 15 patients, 11 patients presented signs that suggested 
mesenteric vasculitis; the prominent mesenteric vessels 
were pale (comb sign), the focal or diffuse handles showed 
distension and the ascites and intestinal wall thickening 
were indicated by a double halo (target sign). The authors 
emphasized that the comb sign reflects an active vascular 
inflammatory reaction and can be extremely useful for 
confirming the diagnosis of mesenteric vasculitis in an initial 
phase of the disease. An early diagnosis is associated with a 
better prognosis.8 Other authors have also confirmed these 
findings.9
The vasculitis can be demonstrated by mesenteric 
vasculature arteriography, which shows the irregularity of 
the vascular branches, mainly in the region of the superior 
mesenteric artery. Angioresonance and scintigraphy with 
gallium are methods that can also be used to do the diagnosis 
ofmesenteric vasculitis. Rheumatic evaluation and follow up 
with a surgeon are extremely important so the patient can 
avoid abdominal surgical emergencies when the abdominal 
tomography indicates the presence of vasculitis. In addition, 
other diverse abdominal pathologies must be excluded, such 
as acute cholecystitis, appendicitis, intestinal occlusion, a 
perforated peptic ulcer, pancreatitis, bacterial peritonitis and 
intestinal infection by cytomegalovirus, tuberculous colitis, 
pelvic inflammatory illness and pyelonephritis. Causes 
of intestinal vascular ischemia, such as atherosclerosis, 
embolism and anti-phospholipids syndrome, must also be 
excluded.10
The absence or delayed appearance of clinical 
manifestations associated with lupus, the production of anti-
dsDNA antibody and the reduction of complement in the 
present patient makes this case note-worthy. The literature 
affirms that mesenteric vasculitis occurs in individuals 
showing lupus activity in other organs and systems, 
generally with a SLEDAI above eight.11,12 In the current 
patient’s situation, evaluation by non-invasive imaging was 
imperative because emergency abdominal surgery must be 
readily excluded in the presence of a low SLEDAI score. In 
fact, among 51 patients with SLE who presented with acute 
abdominal pain, the 19 patients with mesenteric vasculitis 
had a SLEDAI score higher than that of the other 14 lupus 
patients with acute abdominal pain unrelated to the illness 
(17.5 versus 8.2). The authors emphasized the importance of 
using laparotomy in lupus patients who presented with acute 
abdominal pain and a higher SLEDAI index.11
The hydronephrosis as found in our patient was previously 
described in the literature. Mesenteric vasculitis is associated 
with pyelo-ureteral smooth musculature alterations in 67% of 
cases involving pyelo-ureteral hydronephrosis.13 Treatment 
Figure 3 - Delayed arteriography phase showing hydronephrosis on the right 
pyelocaliceal renal system.
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improves the prognosis, and methylprednisolone (1 mg/kg/
day) is employed along with intestinal rest. Generally, a quick 
and effective response is achieved with this treatment. In 
those cases that clinical response is not achieved, surgical re-
evaluation is mandatory to remove the bowel segment having 
ischemia or intestinal perforation away from the digestive 
tract.2 Pulse therapy with methylprednisolone may be required 
in some cases. The use of immunosuppressive drugs generally 
manages disease, but no controlled and randomized studies 
have been performed to demonstrate which drugs are most 
effective or what the best application scheme is. In the present 
case, cyclophosphamide was chosen due to the gravity of the 
clinical picture. 
The present case calls attention to the presence of 
mesenteric vasculitis in lupus patients without systemic 
activity or excessive illness. The use of CT scans in lupus 
patients with abdominal pain is basic, can exclude surgical 
pathologies and aids in making the diagnosis of intestinal 
vasculitis. 
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